Uptake of the levonorgestrel intrauterine system among recent postpartum women in Kenya: Factors associated with decision-making

Contraception

Volumn 88, Issue 1, 2013, Pages 97-102

  Hubacher, David ^a   Masaba, Rose ^a   Manduku, Carolyne Kemunto ^a   Veena, Valentine ^a  

^a FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

Acceptability; Choice; Decision making; Levonorgestrel intrauterine system; Long acting reversible contraception; Postpartum

Indexed keywords

COPPER INTRAUTERINE DEVICE; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; CONTRACEPTION; DECISION MAKING; DERMAL IMPLANT; DRUG UPTAKE; FAMILY PLANNING; FEAR; FEMALE; HUMAN; INJURY; KENYA; MAJOR CLINICAL STUDY; MENSTRUATION; PAIN; PILL; PROSPECTIVE STUDY; SIDE EFFECT;

ADOLESCENT; ADULT; COHORT STUDIES; COMMUNITY HEALTH CENTERS; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; DECISION MAKING; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAUTERINE DEVICES, COPPER; INTRAUTERINE DEVICES, MEDICATED; KENYA; LEVONORGESTREL; PATIENT ACCEPTANCE OF HEALTH CARE; POSTPARTUM PERIOD; PROGESTINS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84879074603     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2013.03.001     Document Type: Article

References (15)

1. A. Conde-Agudelo, and J.M. Belizan Maternal morbidity and mortality associated with interpregnancy interval: cross sectional study BMJ 321 2000 1255 1259
2. J. Cleland, A. Conde-Agudelo, H. Peterson, J. Ross, and A. Tsui Contraception and health Lancet 380 2012 149 156
3. The Millennium Development Goals report. New York: United Nations; 2010 [cited 2011 March 3, 2011]; Available from: http://www.un.org/millenniumgoals/ pdf/MDG%20Report%202010%20En%20r15%20-low%20res%2020100615%20-.pdf
4. WHO Family planning handbook: a global handbook for providers. Baltimore and Geneva: Department of Reproductive Health and Research Johns Hopkins Bloomberg School of Public Health Center for Communication Programs INFO Project; 2011 [cited 2012 January 30]; Available from: http://www. globalhandbook.org/
5. World Health Organization medical eligibility criteria for contraceptive use 3rd ed. 2004 WHO Geneva [cited 2010]; Available from: http://whqlibdoc.who. int/publications/2004/9241562668.pdf
6. World contraceptive use 2011. United Nations [8 November 2012]; Available from: http://www.un.org/esa/population/publications/contraceptive2011/ wallchart-front.pdf
7. International Contraceptive Access (ICA) Foundation home page. International Contraceptive Access (ICA) Foundation Available from: http://www.ica-foundation.org/
8. A.M. Kaunitz, F. Bissonnette, I. Monteiro, E. Lukkari-Lax, Y. Desanctis, and J. Jensen Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels Contraception 86 2012 452 457
9. Medicines360. Available from: http://www.medicines360.org/.
10. A study of a levonorgestrel-releasing intrauterine system for long-term, reversible contraception. Clintrials.gov. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00995150?term=medicines360&rank=1
11. Hormonal IUD. Uteron Pharma; Available from: http://www.odyssea-pharma. be/Hormonal-IUD.html?lang=en.
12. R.H. Allen, D. Bartz, D.A. Grimes, D. Hubacher, and P. O'Brien Interventions for pain with intrauterine device insertion Cochrane Database Syst Rev 2009 CD007373 [Review]
13. D. Hubacher, L. Lopez, M.J. Steiner, and L. Dorflinger Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons Contraception 80 2009 113 118
14. I. Sivin, S. el Mahgoub, T. McCarthy, D.R. Mishell Jr., D. Shoupe, and F. Alvarez Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study Contraception 42 1990 361 378
15. K. Andersson, V. Odlind, and G. Rybo Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial Contraception 49 1994 56 72